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Significant drug-drug interactions (DDIs) occur between calcineurin inhibitors (CNIs) and ART. 2, 3 In a recent study of 332 HIV-positive kidney transplant recipients, a 1.8-and 1.9-fold increased risk of allograft loss and death resulted, respectively, in 88 patients receiving protease inhibitor (PI)-based regimens compared with 244 patients on non-PIbased ART. 4 If possible, eligible HIV-positive recipients should be converted to a non-PI-based regimen prior to or after kidney transplantation.
Tacrolimus is the CNI of choice in HIV-positive renal transplant recipients but has a narrow therapeutic index requiring close drug monitoring to avoid common adverse effects (nephrotoxicity and neurotoxicity) with supratherapeutic concentrations.
2,5 CNI dose conversion after PI discontinuation is variable, with tacrolimus (TAC) dose escalation of 5 to 20 times the original dose. 6, 7 We report on 2 HIV-positive renal transplant recipients who were successfully switched from ritonavir (RTV)-boosted ART to dolutegravir or rilpivirine necessitating a 10-to 24-fold TAC dose escalation to maintain therapeutic concentrations.
Patient 1 is a 68-year-old male with HIV/hepatitis B (viral loads [VL] undetectable), deceased donor kidney transplant (DDKT), and hypertension. After 2 years of concurrent mycophenolate mofetil, prednisone, and TAC (0.2 mg weekly) (stable serum creatinine [SCr] 1.16-1.30 mg/ dL) with fixed dose combination (FDC) abacavir/lamivudine and twice daily DRV)/RTV/etravirine/raltegravir, ART was simplified to abacavir 600 mg/dolutegravir 50 mg/ lamivudine 300 mg. TAC was empirically adjusted 10-fold with weekly concentrations remaining at goal (5-7 ng/mL; Figure 1 ). After dolutegravir transition, the SCr increased (2.28 mg/dL), resulting in an allograft biopsy demonstrating no acute rejection but chronic antibody-mediated changes with early transplant glomerulopathy. The SCr has remained stable for the following 2 years. A similar report describes a DDKT HIV-positive recipient receiving DRV/RTV/raltegravir. 7 ART simplification to FDC dolutegravir/abacavir/lamivudine necessitated a 20-fold TAC dose increase (0.5 mg every 11th day to 5 mg twice daily) after PI discontinuation. The SCr subsequently rose (+0.4 mg/dL) with a negative biopsy. Dolutegravir's inhibition of organic cationic transporter-2 (OCT-2) in the renal tubule was suspected (similar to Patient 1). Rilpivirine also inhibits OCT-2 and a small SCr rise of 0.1 mg/dL is common but does not result in an alteration in the actual glomerular filtration rate. Additional caution should be given to substituting cobicistat-boosted ART in HIV-positive renal transplant recipients as a probable DDI with TAC exists and resulted in supratherapeutic TAC concentrations (111.2 ng/mL) in one reported case. 8, 9 genotypes and in consultation with an HIV infectious disease specialist, HIV-positive candidates should be switched prior to planned renal transplant as post-allograft ART conversions will require weekly evaluations to maintain therapeutic CNI concentrations and HIV viral rebound (similar to the present cases). RTV or cobicistat-boosted regimens should be changed to ART devoid of cytochrome P450 CNI DDIs (dolutegravir, maraviroc, raltegravir, or rilpivirine or the soon to be approved bictegravir) to prolong allograft survival. 3 If ARV resistance does not allow PI or cobicistat-boosted ART discontinuation, alternative immunosuppressive strategies (belatacept) devoid of CNI DDIs is recommended. 
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